Laura E. Niklason - 16 Nov 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
16 Nov 2025
Net transactions value
$0
Form type
4
Filing time
17 Nov 2025, 17:48:26 UTC
Previous filing
20 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Niklason Laura E President, CEO and Director, Director 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact 17 Nov 2025 0001878075

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +311,100 $0.000000 311,100 16 Nov 2025 Common Stock 311,100 $1.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.